A comparative study of the clinical efficacy and safety of agomelatine 25 mg (or 50 mg) with escitalopram 10 mg (or 20 mg) in major depressive disorder patients:a 24 weeks randomized open label parallel group study. - RACE

Government Medical College0 个研究点目标入组 70 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•i) Age should be between 18-65 years with normal liver function.
•ii) Patient should be newly diagnosed of Major Depressive Disorder(MDD)-Patient who first time consult psychiatrist for the complaints suggestive of Major Depressive Disorder(MDD).
•iii) Patient is willing to give written informed consent.

•i) Pregnant and Nursing Women
•ii)Patientâ??s on other antidepressants.
•iii)Patient with high risk of suicide or previous suicide attempt within 6 months, bipolar disorder, anxiety symptoms such as panic attacks, obsessive-compulsive disorder, posttraumatic stress disorder, drug abuse or dependency, previous depression resistant to antidepressants, and treatment with electroconvulsive therapy within 3 months or formal psychotherapy within 1 month.
•iv)Patient with neurologic disorders (dementia, seizures, stroke), obesity with functional impairment, serious or not stabilized organic disorders (neoplasia, cardiovascular, pulmonary, uncontrolled type 1 or 2 diabetes)
•v)Patient with â??resistant depressionâ?? defined as patients who have not responded to two different previous antidepressant treatment for at least four weeks at an appropriate dose.[9]
•v)Shift workers, women without effective contraception

发起方